Antihypertensive Drugs and Risk of Cancer: Between Scylla and Charybdis
Elias Sanidas, Maria Velliou, Dimitrios Papadopoulos, Anastasia Fotsali, Dimitrios Iliopoulos, Marina Mantzourani, Konstantinos Toutouzas, John Barbetseas
Abstract
Antihypertensive drugs namely angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta blockers, and diuretics are among the most clearly documented regimens worldwide with an overall cardioprotective benefit. Given that malignancy is the second leading cause of mortality, numerous observational studies aimed to investigate the carcinogenic potential of these agents with conflicting results. The purpose of this review was to summarize current data in an effort to explore rare side effects and new mechanisms linking antihypertensive drugs with the risk of developing cancer.